Skip to content

Study · Not a test of the peptide alone · 1990

3 results

Synthesis of a thymosin beta 4-like peptide, thymosin beta Met9, and its effect on low E-rosette-forming lymphocytes of lupus nephritis patients.

Abiko T, Sekino H

Chemical & pharmaceutical bulletin1 Aug 1990Cited by 3 (Europe PMC)

PMID2279297 (opens in a new tab)DOI10.1248/cpb.38.2301 (opens in a new tab)PepBankPUB-02279297
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01LabNot a test of Thymosin beta-4 (human) aloneEx vivo tissueActivity measurement

    In peripheral blood from lupus nephritis patients, incubation with synthetic thymosin beta Met9, a thymosin beta‑4-like peptide, increased the E-rosette-forming lymphocytes.

    In plain wordsIn lab tests on lupus nephritis blood samples, a peptide similar to thymosin beta‑4 increased E-rosette-forming lymphocytes.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseE-rosette-forming lymphocytes
    Study

    humann: not reported in source

    peripheral blood from lupus nephritis patients
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The increase of the E-rosette-forming lymphocytes was obtained after incubation of peripheral blood from lupus nephritis patients with the synthetic thymosin beta Met9.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02LabNot a test of Thymosin beta-4 (human) aloneEx vivo tissueActivity measurement

    Synthetic thymosin beta Met9 was approximately equal in potency to synthetic calf thymosin beta 9.

    In plain wordsIn lab tests, thymosin beta Met9 had about the same potency as synthetic calf thymosin beta 9.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changePotency compared with synthetic calf thymosin beta 9
    Study

    humann: not reported in source

    peripheral blood from lupus nephritis patients
    Comparator
    Synthetic calf thymosin beta 9
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    The synthetic thymosin beta Met9 was approximately equal in potency to that of our synthetic calf thymosin beta 9.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Other

    A thymosin beta‑4-like peptide, thymosin beta Met9, was made by a conventional solution synthesis method.

    In plain wordsIn the lab, a peptide similar to thymosin beta‑4, called thymosin beta Met9, was made by chemical synthesis.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableChemical synthesis of thymosin beta Met9
    Study

    n: not reported in source

    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    A thymosin beta 4-like peptide, thymosin beta Met9 isolated from pork spleen, was synthesized using a conventional solution method.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.